Literature DB >> 15303991

Human African trypanosomiasis amongst urban residents in Kinshasa: a case-control study.

J Robays1, A Ebeja Kadima, P Lutumba, C Miaka mia Bilenge, V Kande Betu Ku Mesu, R De Deken, J Makabuza, M Deguerry, P Van der Stuyft, M Boelaert.   

Abstract

BACKGROUND: Increasing numbers of human African trypanosomiasis (HAT) cases have been reported in urban residents of Kinshasa, Democratic Republic Congo since 1996. We set up a case-control study to identify risk factors for the disease.
METHODS: All residents of the urban part of Kinshasa with parasitologically confirmed HAT and presenting for treatment to the city's specialized HAT clinics between 1 August, 2002 and 28 February, 2003 were included as cases. We defined the urban part as the area with contiguous habitation and a population density >5000 inhabitants per square kilometre. A digital map of the area was drawn based on a satellite image. For each case, two serologically negative controls were selected, matched on age, sex and neighbourhood. Logistic regression models were fitted to control for confounding.
RESULTS: The following risk factors were independently associated with HAT: travel, commerce and cultivating fields in Bandundu, and commerce and cultivating fields in the rural part of Kinshasa. No association with activities in the city itself was found. DISCUSSION: In 2002, the emergence of HAT in urban residents of Kinshasa appears mainly linked to disease transmission in Bandundu and rural Kinshasa. We recommend to intensify control of these foci, to target HAT screening in urban residents to people with contact with these foci, to increase awareness of HAT amongst health workers in the urban health structures and to strengthen disease surveillance.

Entities:  

Mesh:

Year:  2004        PMID: 15303991     DOI: 10.1111/j.1365-3156.2004.01266.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  8 in total

1.  African Trypanosomiasis: Changing Epidemiology and Consequences.

Authors:  Jean-Paul Chretien; Bonnie L Smoak
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

2.  Case Report: Trypanosoma brucei Gambiense Human African Trypanosomiasis as the Cause of Fever in an Inpatient with Multiple Myeloma and HIV-1 Coinfection.

Authors:  Carl Boodman; Michael Libman; Momar Ndao; Cedric P Yansouni
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

Review 3.  Human African trypanosomiasis in endemic populations and travellers.

Authors:  J A Blum; A L Neumayr; C F Hatz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-07       Impact factor: 3.267

4.  Population-dynamics focussed rapid rural mapping and characterisation of the peri-urban interface of Kampala, Uganda.

Authors:  K Makita; E M Fèvre; C Waiswa; M D C Bronsvoort; M C Eisler; S C Welburn
Journal:  Land use policy       Date:  2010-07

5.  Human African trypanosomiasis transmission, Kinshasa, Democratic Republic of Congo.

Authors:  Gustave Simo; Philemon Mansinsa Diabakana; Victor Kande Betu Ku Mesu; Emile Zola Manzambi; Gaelle Ollivier; Tazoacha Asonganyi; Gerard Cuny; Pascal Grébaut
Journal:  Emerg Infect Dis       Date:  2006-12       Impact factor: 6.883

6.  Human African trypanosomiasis in the Democratic Republic of the Congo: disease distribution and risk.

Authors:  Crispin Lumbala; Pere P Simarro; Giuliano Cecchi; Massimo Paone; José R Franco; Victor Kande Betu Ku Mesu; Jacquies Makabuza; Abdoulaye Diarra; Shampa Chansy; Gerardo Priotto; Raffaele C Mattioli; Jean G Jannin
Journal:  Int J Health Geogr       Date:  2015-06-06       Impact factor: 3.918

Review 7.  Epidemiology of human African trypanosomiasis.

Authors:  Jose R Franco; Pere P Simarro; Abdoulaye Diarra; Jean G Jannin
Journal:  Clin Epidemiol       Date:  2014-08-06       Impact factor: 4.790

Review 8.  Host Immune Responses and Immune Evasion Strategies in African Trypanosomiasis.

Authors:  Chukwunonso Onyilagha; Jude Ezeh Uzonna
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.